Detailed view for LmjF.33.1710

Basic information

TDR Targets ID: 27540
Leishmania major, protein kinase, putative
Source Database / ID:  TriTrypDB  GeneDB

pI: 6.383 | Length (AA): 640 | MW (Da): 72193 | Paralog Number: 0

Signal peptide: N | GPI Anchor: N | Predicted trans-membrane segments: 0

Druggability Group : DG2

Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable

Pfam domains

PF00069   Protein kinase domain
PF13499   EF-hand domain pair
PF13833   EF-hand domain pair

Gene Ontology

Mouse over links to read term descriptions.
GO:0005509   calcium ion binding  
GO:0004713   protein tyrosine kinase activity  
GO:0004674   protein serine/threonine kinase activity  
GO:0004672   protein kinase activity  
GO:0005524   ATP binding  
GO:0006468   protein amino acid phosphorylation  

Metabolic Pathways

This gene is not mapped to any metabolic pathway in KEGG.

Structural information

Modbase 3D models:

There are 7 models calculated for this protein. More info on these models, including the models themselves is available at: Modbase

Target Beg Target End Template Template Beg Template End Identity Evalue Model Score MPQS zDope
1 366 1kob (A) 23 374 20.00 0 1 0.56 -0.42
342 551 2be4 (A) 9 227 21.00 0.000000065 0.94 0.33 0.66
429 500 2ami (A) 1 74 31.00 0.00000000062 0.85 0.55 -1.41
22 501 3q5i (A) 48 517 27.00 0 1 0.9736 0.03
30 303 3mn3 (A) 53 318 44.00 0 1 0.889025 -0.43
30 305 4czu (A) 29 305 41.00 0 1 0.99015 -0.81
341 405 2auc (A) 140 200 30.00 0.011 1 0.597162 -1.79

Help me make sense of these data.

Target Beg: first modeled residue
Target End: last modeled residue
Template: template structure used for modelling (PDB accession and chain)
Template Beg: first template residue in target-template alignment
Template End: last template residue in target-template alignment
Identity: sequence identity
Evalue: E value for target-template hit
Model Score: GA341 score (>0.7 for reliable model)
MPQS: ModPipe Quality Score (>1.1 for reliable model)
zDope: zDope Score (negative for reliable model)

A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.

PDB Structures:

No structure availble in the PDB for this protein

Expression

Upregulation Percent Ranking Stage Dataset
Upper 80-100% percentile metacyclic. Fernandes MC
Upregulation Percent Ranking Stage Dataset
Upper 60-80% percentile amastigotes. Fernandes MC
Show/Hide expression data references
  • Fernandes MC Dual Transcriptome Profiling of Leishmania-Infected Human Macrophages Reveals Distinct Reprogramming Signatures.

Orthologs

Ortholog group members (OG5_139237)

Species Accession Gene Product
Leishmania braziliensis LbrM.33.1980   protein kinase, putative
Leishmania donovani LdBPK_331810.1   protein kinase, putative
Leishmania infantum LinJ.33.1810   protein kinase, putative
Leishmania major LmjF.33.1710   protein kinase, putative
Leishmania mexicana LmxM.32.1710   protein kinase, putative
Trypanosoma brucei gambiense Tbg.972.2.370   protein kinase, putative
Trypanosoma brucei Tb927.2.1820   CAMK/CAMKL family protein kinase, putative
Trypanosoma congolense TcIL3000_0_19260   protein kinase, putative
Trypanosoma congolense TcIL3000_2_60   protein kinase, putative
Trypanosoma cruzi TcCLB.509213.160   CAMK/CAMKL family protein kinase, putative
Trypanosoma cruzi TcCLB.510257.130   CAMK/CAMKL family protein kinase, putative
Theileria parva TP01_0983   calcium-dependent protein kinase, putative

Essentiality

LmjF.33.1710 has one or more orthologs with essentiality data
Gene/Ortholog Organism Phenotype Source Study
Tb927.2.1820 Trypanosoma brucei no significant loss or gain of fitness in bloodstream forms (3 days) alsford
Tb927.2.1820 Trypanosoma brucei significant loss of fitness in bloodstream forms (6 days) alsford
Tb927.2.1820 Trypanosoma brucei significant loss of fitness in procyclic forms alsford
Tb927.2.1820 Trypanosoma brucei no significant loss or gain of fitness in differentiation of procyclic to bloodstream forms alsford
Show/Hide essentiality data references
  • blattner Systematic mutagenesis of the E. coli (MG1655) genome J Bacteriol 2004, 186:4921-4930
  • alsford High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome Genome Res 2011, 21:915-924
  • nmpdr Genome-scale essentiality datasets from published studies (M. tuberculosis) National Microbial Pathogen Data Resource
  • plasmo Functional Profiling of a Plasmodium Genome Reveals an Abundance of Essential Genes. Bushell, Ellen, et al. "Functional profiling of a Plasmodium genome reveals an abundance of essential genes." Cell 170.2 (2017): 260-272.
  • wormbase C. elegans RNAi experiments WormBase web site, http://www.wormbase.org, release WS170
  • goodall The Essential Genome of Escherichia coli K-12 (Transposon directed high-throughput mutagenesis) Goodall, Emily CA, et al. "The essential genome of Escherichia coli K-12." mBio 9.1 (2018): e02096-17.
  • keio Systematic single-gene knock-out mutants of E. coli K12 The Keio Collection
  • sidik A Genome-wide CRISPR Screen in Toxoplasma Identifies Essential Apicomplexan Genes. Sidik, Saima M., et al. "A genome-wide CRISPR screen in toxoplasma identifies essential apicomplexan genes." Cell 166.6 (2016): 1423-1435.
  • shigen Profiling of E. coli Chromosome (PEC) National Institute of Genetics, Japan
  • neb C. elegans RNAi phenotypes Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs
  • gerdes Experimental determination and system-level analysis of essential genes in E. coli MG1655 Gerdes et al., J Bacteriol. 2003 185:5673-84
  • yeastgenome Systematic deletion of yeast genes Saccharomyces Genome Database

Phenotypes and Validation (curated)

We have no manually annotated phenotypes for this target. What does this mean? / Care to help?

In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.

In any case, if you have information about papers containing relevant validation data for this target, please contact us.

Annotated validation

No validation data for this target

Associated compounds / Druggability

Druggability index (range: 0 to 1): 0.5

Known modulators for this target

No chemical compounds associated to this gene

Predicted associations

By orthology with druggable targets
Non orthologous druggable targets
By sequence similarity to non orthologous druggable targets
Species Target Length Identity Alignment span Linked Drugs Reference
Triticum aestivum Calcium dependent protein kinase 548 aa 28.7% 470 aa Compounds References
Plasmodium falciparum (isolate 3D7) Calcium-dependent protein kinase 4 528 aa 27.5% 488 aa Compounds References
Oryctolagus cuniculus Cyclin-dependent kinase 4 189 aa 30.2% 159 aa Compounds References
Rattus norvegicus Mitogen-activated protein kinase 1 358 aa 27.3% 311 aa Compounds References
Zea mays CaM kinase I alpha 492 aa 29.1% 436 aa Compounds References
Schizosaccharomyces pombe 972h- Casein kinase II subunit alpha 332 aa 21.5% 302 aa Compounds References
Plasmodium falciparum (isolate 3D7) Cell division control protein 2 homolog 288 aa 28.8% 288 aa Compounds References
Rattus norvegicus Cell division protein kinase 5 292 aa 26.6% 293 aa Compounds References
Rattus norvegicus MAP kinase p38 alpha 360 aa 26.3% 308 aa Compounds References
Homo sapiens Cyclin-dependent kinase 1/cyclin B1 297 aa 25.2% 286 aa Compounds References
Bos taurus Glycogen synthase kinase-3 beta splice variant X1 419 aa 27.8% 356 aa Compounds References
Rattus norvegicus Serine/threonine-protein kinase pim-3 326 aa 33.3% 267 aa Compounds References
Obtained from network model

Ranking Plot

Putative Drugs List

Compound Raw Global Species
0.0059 1 1
0.0007 0.5 0.5
0.0007 0.5 0.5
0.0003 0.5 0.5
0.0033 1 1
0.0059 1 1
0.0062 0.6935 0
0.0067 0.5 0.5
0.0091 1 0.5
0.0063 1 1
0.0039 0.5 0.5
0.0026 0.5 0.5
0.0037 1 0.5
0.0066 0.3101 0
0.0018 0.5 0.5
0.0011 1 0.5
0.0039 0.5 0.5
0.0033 0.5 0.5
0.0081 0.5 0.5
0.0012 0.5 0.5
0.0036 0.5 0.5
0.0059 1 1
0.0022 0.5 0.5
0.0029 0.5 0.5
0.0016 0.5 0.5
0.0069 0.3067 1
0.0063 0.7244 0.2543
0.0008 0.5 0.5
0.0056 1 0.5
0.0081 1 0.5
0.0042 0.5 0.5
0.0098 0.3242 0.2614
0.0064 0.3377 0
0.0032 0.5 0.5
0.0016 0.5 0.5
0.0012 0.5 0.5
0.0004 0.5 0.5
0.0023 0.5 0.5
0.0012 0.5 0.5
0.0032 0.5 0.5
0.0093 0.8828 0
0.0092 1 0.5
0.0039 0.9485 0.5
0.0007 0.5 0.5
0.0088 0.4477 1
0.0061 0.6883 0.5304
0.0027 1 0.5

Assayability

Assay information

No assay information for this target.

Reagent availability

No reagent availability information for this target.

Bibliographic References

No literature references available for this target.

If you have references for this gene, please enter them in a user comment (below) or Contact us.

User comments

No user comments are available for this gene. Log in to add comments, or register.

Enter your comment

User ()
Gene identifier LmjF.33.1710 (Leishmania major), protein kinase, putative
Title for this comment
Comment